6-肼基烟酰胺 | 69879-23-8

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡啶及其衍生物
• 中文名称: 6-肼基烟酰胺
• 英文名称: 6-hydrazinonicotinamide
• 英文别名: HYNIC；6-hydrazinylpyridine-3-carboxamide
• CAS: 69879-23-8
• 化学式: C₆H₈N₄O
• 分子量: 152.156
• InChiKey: XHNXJRVXHHTIKS-UHFFFAOYSA-N

物化性质

• 沸点：
  372.3±52.0 °C(Predicted)
• 密度：
  1.50±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  0.6
• 重原子数：
  11
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  94
• 氢给体数：
  3
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  human serum albumin 、 6-肼基烟酰胺 生成 HYNIC-HSA
  参考文献：
  名称：

  摘要：

  DOI：

文献信息

• [EN] HSP90-TARGETING CONJUGATES AND FORMULATIONS THEREOF<br/>[FR] CONJUGUÉS CIBLANT LA HSP90 ET FORMULATIONS ASSOCIÉES
  申请人：TARVEDA THERAPEUTICS INC

  公开号：WO2019195384A1

  公开（公告）日：2019-10-10

  Conjugates of an active agent attached to a targeting moiety, such as at least one HSP90 binding moiety, via a linker, have been designed. Such conjugates can provide improved temporospatial delivery of the active agent, improved biodistribution and penetration in tumor, and/or decreased toxicity. Methods of making the conjugates and the formulations thereof are provided. Methods of administering the formulations to a subject in need thereof are provided, for example, to treat or prevent cancer.

  已设计出将活性剂与靶向基团（例如至少一个HSP90结合基团）通过连接剂结合的共轭物。这种共轭物可以提供改善活性剂的时间空间传递、改善在肿瘤中的生物分布和穿透性，以及/或减少毒性。提供了制备这些共轭物及其配方的方法。提供了将这些配方用于治疗或预防癌症等需要的受试者的方法。
• Chelants and macrocyclic metal complex radiopharmaceuticals thereof
  申请人：Liu Shuang

  公开号：US20050010038A1

  公开（公告）日：2005-01-13

  Chelants and macrocyclic metal complexes thereof, methods of preparing the chelants and macrocyclic metal complexes, and radiopharmaceutical compositions comprising the macrocyclic metal complexes are disclosed. Methods of using the macrocyclic metal complexes as radiopharmaceuticals for the diagnosis of cardiovascular disorders, infectious diseases and cancer are also disclosed. Chelants as bifunctional chelators (BFCs) for the radiolabeling of target-specific biomolecules, such as proteins, peptides, peptidomimetics, non-peptide receptor ligands, enzyme inhibitors, and enzyme substrates are disclosed. Methods of using macrocyclic metal complexes containing the chelant-biomolecule conjugates as target-specific diagnostic radiopharmaceuticals that selectively localize at sites of disease and allow an image to be obtained of the loci using gamma scintigraphy are disclosed. Methods of use of the radiopharmaceuticals as imaging agents for the diagnosis of cardiovascular disorders, such as thromboembolic disease or atherosclerosis, infectious disease and cancer are further disclosed.

  螯合剂及其大环金属配合物，制备螯合剂和大环金属配合物的方法，以及包括大环金属配合物的放射性药物组合物被揭示。还揭示了将大环金属配合物用作用于诊断心血管疾病、传染病和癌症的放射性药物的方法。揭示了作为靶向特定生物分子（如蛋白质、肽、肽类似物、非肽受体配体、酶抑制剂和酶底物）的放射标记的双功能螯合剂（BFCs）的螯合剂。揭示了使用含有螯合剂-生物分子共轭物的大环金属配合物作为靶向特定诊断放射性药物的方法，这些药物选择性地定位于疾病部位，并允许使用伽马闪烁术获得部位的图像。进一步揭示了将放射性药物用作心血管疾病（如血栓栓塞病或动脉粥样硬化）、传染病和癌症的诊断成像剂的方法。
• [EN] HSP90-BINDING CONJUGATES AND FORMULATIONS THEREOF<br/>[FR] CONJUGUÉS LIÉS À HSP90 ET FORMULATIONS DE CEUX-CI
  申请人：TARVEDA THERAPEUTICS INC

  公开号：WO2020205948A1

  公开（公告）日：2020-10-08

  Conjugates of an active agent attached to a targeting moiety, such as at least one HSP90 binding moiety, via a linker, have been designed. Such conjugates can provide improved temporospatial delivery of the active agent, improved biodistribution and penetration in tumor, and/or decreased toxicity. Methods of making the conjugates and the formulations thereof are provided. Methods of administering the formulations to a subject in need thereof are provided, for example, to treat or prevent cancer.

  将附着到靶向基团上的活性药剂的共轭物，例如至少一个HSP90结合基团，通过连接剂设计。这样的共轭物可以提供改善的活性药剂的时间空间传递，改善在肿瘤中的生物分布和渗透，以及/或减少毒性。提供了制备这些共轭物和其配方的方法。提供了将这些配方用于需要的受试者的方法，例如用于治疗或预防癌症。
• DIAGNOSTIC AGENT FOR INFECTIOUS DISEASES
  申请人：Sakurai Kazuhisa

  公开号：US20120219500A1

  公开（公告）日：2012-08-30

  A diagnostic agent for infectious diseases which is capable of distinguishing among different kinds of bacterial species and which allows simple and non-invasive measurement and/or imaging in a short period of time is provided; and a screening method for a therapeutic agent for infectious diseases caused by microorganisms are provided. A diagnostic agent for infectious diseases caused by nitroimidazole susceptible microorganisms, containing an imidazole derivative or a fused imidazole derivative having at least one nitro group on an imidazole ring, or a labeled form thereof as an active ingredient is provided.

  提供了一种针对传染病的诊断试剂，能够区分不同种类的细菌，并允许在短时间内进行简单、非侵入性的测量和/或成像；同时提供了一种筛选治疗由微生物引起的传染病的方法。提供了一种针对对硝基咪唑敏感微生物引起的传染病的诊断试剂，其包含一种咪唑衍生物或至少在咪唑环上具有一个硝基基团的融合咪唑衍生物，或其标记形式作为活性成分。
• Homogeneous humanized antibodies against JAM-A that inhibit proliferation
  申请人：PIERRE FABRE MEDICAMENT

  公开号：EP2455403A1

  公开（公告）日：2012-05-23

  The present invention relates to humanized antibodies able to inhibit tumor growth, as well as the amino and nucleic acid sequences coding for such antibodies. From one aspect, the invention relates to anti-JAM-A homogeneous humanized antibodies able to inhibit tumor growth. The invention also comprises the use of such antibodies as a drug for the preventive and/or therapeutic treatment of cancers, as well as compositions comprising such antibodies in combination with other anticancer compounds. The invention also relates to a method for the preparation of such humanized antibodies.

  本发明涉及能够抑制肿瘤生长的人源化抗体，以及编码这种抗体的氨基酸和核酸序列。从一个方面来看，该发明涉及能够抑制肿瘤生长的抗JAM-A同源化人源化抗体。该发明还包括将这种抗体用作预防和/或治疗癌症的药物，以及包含这种抗体与其他抗癌化合物组合的组合物。该发明还涉及一种制备这种人源化抗体的方法。